Contribute Try STAT+ Today

It looks like there won’t be any Yelp reviewscolor-coded drugs, or seasteading in the Food and Drug Administration’s future. Instead, President Donald Trump is going with the establishment candidate — and the biotech industry couldn’t be more relieved.

Dr. Scott Gottlieb, a former deputy commissioner at FDA who also has a Wall Street pedigree, is Trump’s nominee to lead the agency, ending months of speculation and consternation among biotech insiders.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • May I observe that until Scott is formally designated as the nominee and the Senate approves him, it is too early to celebrate. While this potential choice counts as a pleasant surprise, the President always seems to have ‘another surprise’ in the wings. Senate confirmation first then pop the corks, assuming, of course, that now the nomination is set.

Comments are closed.